Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the... see more

Recent & Breaking News (NDAQ:OKUR)

Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

GlobeNewswire February 2, 2023

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

GlobeNewswire January 31, 2023

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire November 3, 2022

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

GlobeNewswire August 29, 2022

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

GlobeNewswire August 2, 2022

Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

GlobeNewswire July 26, 2022

Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 11, 2022

Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

GlobeNewswire June 30, 2022

Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 23, 2022

Reneo Pharmaceuticals Announces Senior Leadership Promotions

GlobeNewswire March 7, 2022

Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

GlobeNewswire February 2, 2022

Reneo Pharmaceuticals Announces Changes to its Board of Directors

GlobeNewswire January 24, 2022

Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results

GlobeNewswire November 11, 2021

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire November 1, 2021

Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001

GlobeNewswire October 14, 2021

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

GlobeNewswire October 11, 2021

Podcasts